HSE rules out funding for 'game-changer' cystic fibrosis drug

The HSE has ruled out funding for a new breakthrough drug for cystic fibrosis sufferers.

The Sunday Business Post claims Orkambi, which is the first ever treatment targeting the cause of the condition, would cost €92m each year, the equivalent of annual funding for Temple Street Children's Hospital.